Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: Results of a pooled analysis from 3 phase-II clinical trials - 13/01/15
, Cameron Harrison, MD b, Mahkam Tavallaee, MD, MPH b, Sameer Bashey, MD b, Uma Sundram, MD, PhD b, c, Shufeng Li, MS b, Lynn Million, MD a, Bouthaina Dabaja, MD d, Pamela Gangar, MD e, Madeleine Duvic, MD e, Youn H. Kim, MD bAbstract |
Background |
Standard-dose (36-Gy) total skin electron beam therapy (TSEBT) is a highly effective treatment in mycosis fungoides. However, the regimen is time-intensive and may be associated with significant toxicity.
Objective |
We sought to evaluate the efficacy and tolerability associated with low-dose (12-Gy) TSEBT.
Methods |
Data from 3 clinical trials using low-dose (12-Gy) TSEBT were pooled. In all trials, TSEBT-naïve patients with stage IB to IIIA mycosis fungoides were treated with TSEBT (12 Gy, 1 Gy per fraction over 3 weeks). The primary end point was clinical response rate. Secondary end points included time to response and duration of clinical benefit.
Results |
In all, 33 patients enrolled. Eighteen were male; stages were 22 IB, 2 IIA, 7 IIB, and 2 IIIA. Overall response rate was 88% (29/33), including 9 patients with complete response. Median time to response was 7.6 weeks (3-12.4 weeks). Median duration of clinical benefit was 70.7 weeks (95% confidence interval 41.8-133.8 weeks). Toxicities from TSEBT were mild and reversible.
Limitations |
Conclusions are limited because of the small number of patients.
Conclusions |
Low-dose TSEBT provides reliable and rapid reduction of disease burden in patients with mycosis fungoides, which could be administered safely multiple times during the course of a patient's disease with acceptable toxicity profile.
Le texte complet de cet article est disponible en PDF.Key words : cutaneous lymphoma, low-dose total skin electron beam therapy, radiotherapy, T-cell lymphoma, total skin electron beam therapy
Abbreviations used : AE, CR, DOCB, DOR, MF, mSWAT, ORR, PD, PR, TSEBT, TTP, TTR
Plan
| This study was partially supported by the Haas Family Foundation and Merck. |
|
| Conflicts of interest: None declared. |
Vol 72 - N° 2
P. 286-292 - février 2015 Retour au numéro
Article précédent
- Clinical characteristics, prognostic factors, and survival of 393 patients with mycosis fungoides and Sézary syndrome in the southeastern United States: A single-institution cohort
- Megan Desai, Shuling Liu, Sareeta Parker
- Cutaneous manifestations of human T-cell lymphotrophic virus type-1-associated adult T-cell leukemia/lymphoma: A single-center, retrospective study
- Michael A. Marchetti, Melissa P. Pulitzer, Patricia L. Myskowski, Stephen W. Dusza, Matthew A. Lunning, Steven M. Horwitz, Alison J. Moskowitz, Christiane Querfeld
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?